HolderBook

Ishara Investments LP

Reported holdings as of Q2 2026, from 3 quarterly filings.

CIK
2111609
Reported value
$136.1M
Positions
41
Top 10 weight
51.0%
Filed
2026-08-14
Days after quarter end
45

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
ACADIA PHARMACEUTICALS INCACAD$10.4M410,0007.62%+5.03pp3q+233.3%+$7.3M
XERIS BIOPHARMA HOLDINGS INCXERS$9.7M1,230,0007.16%+1.53pp3q+20.0%+$1.6M
BIOMARIN PHARMACEUTICAL INCBMRN$8.2M143,5006.03%+1.65pp3q+75.0%+$3.5M
PRAXIS PRECISION MEDICINES IPRAX$7.5M22,5505.55%-7.58pp3qHELD
ULTRAGENYX PHARMACEUTICAL INRARE$6.8M205,0005.03%+1.57pp3q+17.6%+$1.0M
AGIOS PHARMACEUTICALS INCAGIO$6.1M164,0004.47%-newNEW
INSMED INCINSM$5.5M51,2504.01%-newNEW
CRINETICS PHARMACEUTICALS INCRNX$5.4M143,5003.95%-newNEW
ZENTALIS PHARMACEUTICALS INCZNTL$5.0M1,025,0003.65%+0.93pp3q-16.7%-$994.2K
VAXCYTE INCPCVX$4.8M82,0003.50%+0.34pp3q+42.9%+$1.4M
ANNEXON INCANNX$4.7M820,0003.44%+2.53pp3q+370.6%+$3.7M
TRAVERE THERAPEUTICS INCTVTX$4.7M82,0003.42%+0.31pp2q-25.9%-$1.6M
TONIX PHARMACEUTICALS HLDG CTNXP$4.3M338,2503.17%-newNEW
BRIDGEBIO PHARMA INCBBIO$4.3M57,4003.14%-newNEW
AXSOME THERAPEUTICS INCAXSM$4.0M16,4002.95%-3.61pp2q-60.0%-$6.0M
CONTINEUM THERAPEUTICS INCCTNM$3.4M205,0002.47%+0.71pp2q+44.4%+$1.0M
LEXICON PHARMACEUTICALS INCLXRX$3.1M1,271,0002.24%+0.91pp3q+40.9%+$885.6K
KURA ONCOLOGY INCKURA$3.0M276,7502.23%-newNEW
DBV TECHNOLOGIES S ADBVT$3.0M184,5002.22%+0.20pp2q+80.0%+$1.3M
GENMAB A/SGMAB$2.8M102,5002.07%-0.01pp3q+25.0%+$563.1K
CYTOKINETICS INCCYTK$2.8M32,8002.05%-newNEW
MINERALYS THERAPEUTICS INCMLYS$2.8M102,5002.03%-0.07pp2q+25.0%+$553.1K
SILENCE THERAPEUTICS PLCSLN$2.4M55,3501.79%+1.09pp3q-60.6%-$3.7M
NUVATION BIO INCNUVB$2.1M369,0001.54%-newNEW
WAVE LIFE SCIENCES LTDWVE$1.9M328,0001.40%-newNEW
NEKTAR THERAPEUTICSNKTR$1.9M26,6501.37%-newNEW
SCHOLAR ROCK HLDG CORPSRRK$1.7M30,7501.24%-1.43pp2q-46.4%-$1.5M
ENLIVEN THERAPEUTICS INCELVN$1.7M32,8001.22%-newNEW
ALNYLAM PHARMACEUTICALS INCALNY$1.5M5,1251.13%-0.47pp2qHELD
BEAM THERAPEUTICS INCBEAM$1.4M41,0001.03%-0.26pp3q-28.6%-$562.8K
SIONNA THERAPEUTICS INCSION$1.4M123,0000.99%-0.88pp2q+150.0%+$810.3K
ORIC PHARMACEUTICALS INCORIC$1.3M123,0000.98%-0.25pp3q+20.0%+$222.0K
NEWAMSTERDAM PHARMA COMPANYNAMS$1.3M36,9000.92%-0.20pp3qHELD
VERTEX PHARMACEUTICALS INCVRTX$1.2M2,4600.90%-newNEW
ARS PHARMACEUTICALS INCSPRY$1.1M143,4900.84%-newNEW
MONOPAR THERAPEUTICS INCMNPR$1.1M12,3000.84%-newNEW
ERASCA INCERAS$751.1K41,0000.55%-newNEW
VERA THERAPEUTICS INCVERA$439.8K10,2500.32%-2.80pp2q-87.5%-$3.1M
IMMATICS N.VIMTX$311.5K30,7500.23%-1.20pp3q-80.0%-$1.2M
MEREO BIOPHARMA GROUP PLCMREO$244.2K768,7500.18%-newNEW
GOSSAMER BIO INCGOSS$135.0K820,0000.10%-0.16pp2qHELD

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 100.0%
 
SectorValueShare
Biotech & Pharma$136.1M100.0%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$136.1M41161381151.0%45
Q1 2026$105.6M36171091954.0%45
Q4 2025$87.5M38000055.9%48

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.